| Title |
Novel Therapies for the Treatment of Advanced Prostate Cancer
|
|---|---|
| Published in |
Current Treatment Options in Oncology, January 2013
|
| DOI | 10.1007/s11864-012-0222-4 |
| Pubmed ID | |
| Authors |
J. M. Clarke, A. J. Armstrong |
| Abstract |
In recent years, great success has been achieved on many fronts in the treatment of men with metastatic castration-resistant prostate cancer (CRPC), including novel chemotherapeutics, immunotherapies, bone microenvironment-targeted agents, and hormonal therapies. Numerous agents are currently in early-phase clinical trial development for the treatment of advanced prostate cancer. These novel therapies target several areas of prostate tumor biology, including the upregulation of androgen signaling and biosynthesis, critical oncogenic intracellular pathways, epigenetic alterations, and cancer immunology. Importantly, the characterization of the prostate cancer genome offers the potential to exploit conserved genetic alterations, which may increase the efficacy of these targeted therapies. Predictive and prognostic biomarkers are urgently needed to maximize therapeutic efficacy and safety of these promising new treatments options in prostate cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 2% |
| Germany | 1 | 2% |
| Unknown | 45 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 11 | 23% |
| Student > Ph. D. Student | 6 | 13% |
| Student > Master | 6 | 13% |
| Student > Doctoral Student | 5 | 11% |
| Researcher | 5 | 11% |
| Other | 9 | 19% |
| Unknown | 5 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 32% |
| Agricultural and Biological Sciences | 11 | 23% |
| Biochemistry, Genetics and Molecular Biology | 5 | 11% |
| Social Sciences | 2 | 4% |
| Nursing and Health Professions | 1 | 2% |
| Other | 4 | 9% |
| Unknown | 9 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 November 2023.
All research outputs
#3,150,341
of 22,986,950 outputs
Outputs from Current Treatment Options in Oncology
#51
of 672 outputs
Outputs of similar age
#34,446
of 286,376 outputs
Outputs of similar age from Current Treatment Options in Oncology
#2
of 6 outputs
Altmetric has tracked 22,986,950 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 672 research outputs from this source. They receive a mean Attention Score of 3.2. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,376 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.